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ABSTRACT
Objective To conduct a systematic review to identify
and critically appraise clinical practice guidelines on the
assessment, diagnosis and management of childhood
glaucoma.
Methods and analysis A systematic literature search
of databases and professional websites for clinical practice
guidelines published on eye conditions between 2010 and
April 2020 in English was conducted. Identified guidelines
were screened for relevance to childhood glaucoma
and exclusion criteria applied. Guidelines that passed
the screening and quality appraisal with the Appraisal
of Guidelines for Research and Evaluation II (AGREE
II) tool and, if they achieved a mean score of ≥45 and
≥3 on subsets of 9 and 5 AGREE II items, respectively,
were selected for inclusion and data extracted using a
standardised form.
Results Following screening and critical appraisal, three
guidelines were included for data extraction. None of the
three guidelines was specifically developed for childhood
glaucoma. A consistent recommendation was that children
should undergo some form of eye screening examination
or a comprehensive eye assessment to detect paediatric
eye disease. Children at high risk of childhood glaucoma
should undergo additional screening. One clinical practice
guideline recommended interventions for childhood
glaucoma consisting of tube surgery and topical beta-
blockers or carbonic anhydrase inhibitors. Recommended
interventions for childhood glaucoma were based on low-
quality to moderate-quality evidence or expert opinion.
Conclusion Based on our selection criteria, we did
not identify any high-quality clinical practice guidelines
specifically targeted at childhood glaucoma. This is
compounded by the lack of high-quality evidence on
childhood glaucoma.

INTRODUCTION
Childhood glaucoma is a rare eye condition
with estimated incidence of 2.29 per 100 000
people below 20 years of age in the USA to
5.41 per 100 000 live births in the UK.1 2 A
higher incidence has been reported in Asian
populations.1 3–5 Childhood glaucoma is an
important cause of vision loss and is estimated to be responsible for 10% and 3%
of childhood blindness in African regions
and the USA, respectively.6 Childhood glaucoma is not a single disease entity and may
arise secondary to one or more underlying

Key messages
What is already known about this subject?
► Childhood glaucoma is a rare, but devastating, eye

condition among children, which requires often lifelong management and treatment.

What are the new findings?
► Clinical practice guidelines specifically targeting

childhood glaucoma are scarce.
► This systematic review identified only three guide-

lines, none of which was specific to childhood
glaucoma.

How might these results change the focus of
research or clinical practice?
► This systematic review will inform a Package of Eye

Care Interventions developed by WHO.
► There is need for a high-
quality clinical practice

guideline for childhood glaucoma.

congenital anatomical defects, genetic alterations, neoplastic, infectious, inflammatory
or postsurgical causes. The Childhood Glaucoma Research Network defines childhood
glaucoma as intraocular pressure (IOP)-
related ocular damage and classifies it into
primary and secondary types.7 Primary childhood glaucoma includes primary congenital
glaucoma (PCG) and juvenile open angle
glaucoma. Secondary childhood glaucoma
includes glaucoma associated with non-
acquired ocular anomalies (eg, Axenfeld
Rieger anomaly), non-
acquired systemic
diseases (eg, Down syndrome), acquired
conditions (eg, uveitis) and previous cataract
surgery.7
Despite several available options for
management of childhood glaucoma, the
prognosis is often suboptimal. People with
childhood glaucoma have a reduced quality
of life8 and visual acuity is often poor with
approximately 25% of children with PCG
meeting the WHO’s definition of blindness
in one Indian cohort.9 10 As the disease and
its management essentially requires lifelong
monitoring, there is also a significant impact
on the caregiver quality of life, indicating that
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evidence-based interventions are required at a multitude
of levels to optimise patient outcomes.11
Childhood glaucoma has been identified as a priority
eye condition for inclusion in the WHO’s Package of Eye
Care Interventions (PECI). The PECI is being developed
in response to a recommendation from the World Report
on Vision to imbed eye care into Universal Healthcare
Coverage. The PECI will be an evidence-based tool that
aims to improve access to, and the provision of, eye care
by assisting Member States, particularly low-income and
middle-
income nations, with the planning, budgeting
and integration of eye care interventions.12 For example,
in the context of childhood glaucoma, the PECI will
provide recommendations on cost-
effective, evidence-
based interventions and the resources required to
implement these interventions. Stage 2 of the PECI is a
systematic review of clinical practice guidelines (CPGs) to
identify recommended, evidence-based interventions for
priority eye conditions. Later stages of the PECI development include the review and selection of recommended
interventions for inclusion in the PECI by a panel of
experts from low-
resource, middle-
resource and high-
resource settings, identification of required resources
and peer review of the package.12
This systematic literature review aims to identify CPGs
for childhood glaucoma and extract data to support the
development of the WHO PECI.
METHODS
This systematic review of CPGs was conducted in compliance with the methodology outlined in the introductory
PECI paper.12 A CPG was defined according to the Institute of Medicine definition: ‘statements that include
recommendations, intended to optimise patient care that
are informed by a systematic review of evidence and an
assessment of the benefits and harms of alternative care
options’.13 Exclusion criteria for each stage of screening
are provided in table 1.
Systematic literature search
A systematic literature search for CPGs was conducted
on 9 March 2020 in the following academic databases:

Table 1 Exclusion criteria for screening of CPGs
Reason for exclusion

Title and
abstract
screening

►
►
►
►

Full-text
screening

► There was commercial funding or unmanaged
conflicts of interest present.
► Absence of affiliation of authors.

Quality
appraisal

► The average score of the two researchers for items
4, 7, 8, 12 or 22 is below 3.
► The sum of the average score of the two
researchers for all nine items is <45.

The identified literature was not a CPG.
The guideline was not published in the last 10 years.
The guideline was not in English.
The guideline was not developed for selected eye
conditions.

CPG, clinical practice guideline.

2

MEDLINE, Embase, CINAHL and Global Index Medicus.
In addition, a search of guideline databases and the
websites of several optometry and ophthalmology associations were also undertaken for CPGs that met the
inclusion criteria. The search terms and filters were
adapted according to the search options in the specific
guideline databases and websites. Guidelines were
limited to publication in the last 10 years and published
in English. The full search strategy and list of databases
and websites searched are presented in online supplemental appendix 1.
Title and abstract screening
Title and abstracts of the records identified in the
searches were screened independently by two authors
(GL, SS) using the semi-automated AbstrackR software.14
The following exclusion criteria were applied: the document was not a CPG, the guideline was not published in
the last 10 years, the guideline was not in English or the
guideline was not developed for a priority eye condition
for PECI. Discrepancies were resolved by a representative
from WHO (SK) and Cochrane Eyes and Vision (CEV;
JRE).
Full-text screening
CPGs identified as potentially relevant to childhood glaucoma based on title and abstract screening underwent
independent full-text screening by two authors (GL, ST).
Broadly, guideline relevant to paediatric populations,
glaucoma or some combination of the two were selected
for full-text screening and we opted to be inclusive to avoid
missing eligible guidelines. CPGs were excluded if they
were deemed not relevant to childhood glaucoma, did not
list the affiliations of all authors, did not declare potential conflicts of interest or there were significant conflicts
of interest present. Potentially significant conflicts of
interest included scenarios such as a large proportion
of authors having relevant conflicts of interest, the first
or senior author having a direct, proprietary conflict of
interest or a lack of a description for managing relevant
conflicts of interest, when present. Where it was unclear
whether there was a significant conflict of interest, the
full-text screening team was encouraged to consult with a
third (SK) and fourth author (JRE) from WHO and CEV,
respectively. Other discrepancies were resolved through
discussion between the two authors (GL and ST) or, in
the event a consensus could not be reached, by discussion with the aforementioned third and fourth authors
(SK and JRE).
Quality appraisal
The selected CPGs underwent independent quality
appraisal by two authors (GL, ST) using the Appraisal
of Guidelines for Research and Evaluation II (AGREE
II) tool.15 The AGREE II tool contains 23 items relating
to 6 quality domains: scope and purpose, stakeholder
involvement, rigour of development, clarity of presentation, applicability and editorial independence. Based
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Table 2 Details and AGREE II ratings of clinical practice guidelines that met eligibility criteria
AGREE II ratings of each reviewer separately
Organisation

Region

Included

Publication year

4

7

8

10

12

13

15

22

23

Total

18

AAO

USA

Yes

2017

7
7

7
7

3
5

5
6

6
6

6
6

5
6

7
7

7
7

53
57

AOA19

USA

Yes

2017

NHMRC17

AUS

Yes

2010

Anwar et al26

USA

No

2013

EGS27

EU

No

2014

SOS28

SE

No

2012

7

4

7

6

7

7

6

7

4

55

7

6

7

7

7

7

7

7

5

60

7

4

6

6

5

6

5

6

6

51

7

4

6

5

5

5

5

6

6

49

4

1

1

2

5

4

4

2

6

29

4

1

1

1

3

4

3

2

5

24

7

2

2

4

5

3

5

4

4

3

6

4

5

4

6

5

5

5

4

44

6
6

3
3

6
5

2
2

5
2

4
4

5
5

3
4

5
4

39
35

Titles of the AGREE II items are as follows: 4—the guideline development groups include individuals from all relevant professional groups;
7—systematic methods were used to search for evidence; 8—the criteria for selecting the evidence are clearly described; 10—the methods
for formulating the recommendations are clearly described; 12—there is an explicit link between the recommendations and the supporting
evidence; 13—the guidelines has been externally reviewed by experts prior to publication; 15—the recommendations are specific and
unambiguous; 22—the views of the funding body do not influence the content of the guideline; 23—competing interests of guideline
development group members have been recorded and addressed.
AAO, American Academy of Ophthalmology; AGREE II, Appraisal of Guidelines for Research and Evaluation II; AOA, American Optometric
Association; AUS, Australia; EGS, European Glaucoma Society; EU, Europe; NHMRC, National Health and Medical Research Council; SE,
Sweden; SOS, Swedish Ophthalmolgical Society.

on a consensus finding process prior to this review,16
we only used a subset of AGREE II items to appraise
CPGs, specifically items 4, 7, 8, 10, 12, 13, 15, 22 and 23
(item names provided in table 2). These items are in the
domains of stakeholder involvement, rigour of development, clarity of presentation and editorial independence
and were recommended for use by the WHO Guideline
Review Committee Secretariat, as they were deemed most
relevant to the development of packages of care. To be
eligible for inclusion, the average result for items 4, 7,
8, 12 and 22 had to be ≥3, and the average sum score of
items 4, 7, 8, 10, 12, 13, 15, 22 and 23 had to be >45.
Final guideline selection
To facilitate timely development of the PECI, a maximum
of five CPGs were able to be selected for data extraction.
Where more than five CPGs were eligible, guidelines
were to be selected according to the following criteria:
quality, publication date and comprehensiveness (ie,
applicability to different settings).
Data extraction
Data were extracted from the selected CPGs using a
standardised form that recorded information on the
recommendation (type of recommendation, dosage,
target group, etc), the strength of recommendation and
the quality of the evidence used to inform the recommendation by the guideline development group. Data
were tabulated and organised according to intervention
type: screening, assessment, prevention, promotion or
treatment.

Recommended eye care interventions for childhood
glaucoma were extracted from CPGs by one author (GL
or ST) and independently checked by a second author
(GL or ST). The process was repeated for all the guidelines until agreement on the recommended eye care
interventions was reached.
RESULTS
Screening, appraisal and selection of guidelines
The results of the selection process are reported in
figure 1. After the initial title and abstract screening, 68
reports were identified as potentially relevant to childhood glaucoma. On review of the full-text report, 29 of
these guidelines were deemed not relevant to childhood
glaucoma, 27 did not report either potential conflicts
of interest or affiliations of authors, 1 had significant
conflicts of interest among authors and 5 did not meet
the criteria of a CPG on full-text review, leaving 6 CPGs
for the AGREE II appraisal.
The results of the AGREE II appraisal are shown in
table 2. There was very good overall agreement between
the two raters (one-
way intraclass correlation=0.83).
After the AGREE II appraisal, three of the six CPGs
were excluded: one due to the average score of the two
researchers for items 4, 7, 8, 12 or 22 being <3 and two
CPGs were excluded due to the sum of the average score
of the two researchers for all items being <45. Of the three
CPGs that were excluded during the AGREE II appraisal,
one was aimed at addressing the side effects of glaucoma
therapy while the remaining two were CPGs aimed at all
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Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart summarising the results of the
literature review to identify clinical practice guidelines for childhood glaucoma.

types of glaucoma. These excluded guidelines performed
most poorly in areas relating to reporting of systematic
review methods and methods for formulating recommendations.
We ultimately selected three CPGs17–19 for the data
extraction phase. The extracted recommendations are
shown in table 3. Two of the three included guidelines
were published in the USA and related to the ocular
assessment of children and infants and thus were not
directly aimed at detection and management of childhood glaucoma. These two CPGs had the highest overall
AGREE II scores. The remaining selected CPG was
published in Australia in 2010 and was aimed at diagnosis
and management of glaucoma at all ages and only a small
part of the CPG was dedicated to childhood glaucoma.
Therefore, we did not identify a CPG that specifically
targeted childhood glaucoma.
Guideline recommendations
Of the recommendations extracted, strongly recommended interventions largely related to the assessment
of infants and children to detect eye conditions such as
childhood glaucoma, as well as the assessment of IOP in
the diagnosis and management of glaucoma. Screening
of first-degree relatives of those with glaucoma, including
those with genetic syndromes that are highly associated
with childhood glaucoma, was also strongly recommended.
Tube surgery was strongly recommended for long-term
IOP control in patients at high risk of trabeculectomy
4

failure (such as in childhood glaucoma) and in glaucoma following cataract surgery. Although not formally
recommended, tube surgery was noted to be an appropriate first-line treatment for some secondary causes of
childhood glaucoma. Topical beta-blockers and carbonic
anhydrase inhibitors were recommended with intermediate strength for the management of childhood
glaucoma, although these therapies should be used with
caution due to the potential for adverse events and the
quality of evidence was noted to be low. Surveillance
of patients on long-term steroid medication including
assessment of the optic nerve head, anterior chamber
and visual field was recommended with weak or intermediate strength. These recommendations, however, were
targeted at all individuals with glaucoma or at risk of glaucoma and were not specific to childhood glaucoma.
The quality of evidence used for formulating recommendations varied considerably. Recommendations
relating to the screening or examination of children to
detect paediatric eye disease or certain ocular assessments
for the diagnosis of glaucoma were generally of moderate-
quality or good-quality evidence, with some exceptions.
There was only low-quality evidence to support the use
of topical IOP-lowering medication for the treatment of
childhood glaucoma. Interestingly there was deemed to
be moderate-quality evidence for the use of tube surgery;
however, this recommendation was for the use of tube
surgery where trabeculectomy is likely to fail including,
but not limited to, some childhood glaucomas.17 Thus,
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Table 3 Extracted assessment or intervention recommendations from eligible CPGs
Assessment or
intervention name

Recommendation

CPG

SoR

QoE

Remarks on recommendation

Screening to detect
amblyopia or risk
factors

The 2017 USPSTF report recommends
AAO
vision screening for children aged 3–5
years of age to detect amblyopia or its risk
factors

Strong

Good

 

Examine individuals
with first-degree
relatives with
glaucoma

…first-degree relatives of individuals
NHMRC
diagnosed with glaucoma are considered
at high risk of developing glaucoma
themselves. It is recommended that they
undergo a full ocular examination by a
qualified healthcare provider, and receive
ongoing monitoring for the development of
glaucoma

Strong

Good

The following genetic syndromes
have high associations with
childhood glaucoma: Nail Patella
syndrome with the LMX1B gene,
Axenfeld Rieger syndrome/
anterior segment dysgenesis
with the PITX2 and FOXC1 genes
and Aniridia with the PAX6 gene.
Patients with these syndromes
or mutations are usually followed
closely for glaucoma. Congenital
glaucoma is associated with
Cyp1B1 mutations in 17% of
Australian families.

Monitor long-term
users of steroids for
glaucoma

…long-term users of steroids by any route
of administration are at increased risk of
glaucoma, and thus require surveillance.

Intermediate

Moderate There is no evidence from the
secondary literature regarding the
risk factors for, or progression of
secondary glaucoma.

Comprehensive
eye and vision
examination of infants
(6–12 months of age)

Infants should receive an in-person
AOA
comprehensive eye and vision assessment
between 6 and 12 months of age for
the prevention and/or early diagnosis
and treatment of sight-threatening
eye conditions and to evaluate visual
development

Strong

Moderate  

Comprehensive
eye and vision
examination of
children (3–5 years
of age)

Preschool age children should receive
an in-person comprehensive eye and
vision examination at least once between
the ages of 3 and 5 years to prevent
and/or diagnose and treat any eye or
vision conditions that may affect visual
development

AOA

Strong

Moderate  

Comprehensive
eye and vision
examination before
beginning school

School-age children should receive an
in-person comprehensive eye and vision
examination before beginning school to
diagnose, treat and manage any eye or
vision conditions

AOA

Strong

Moderate  

Annual comprehensive
eye and vision
examination of
school-age children

School-age children should receive an
AOA
in-person comprehensive eye and vision
examination annually to diagnose, treat and
manage eye or vision problems

Not stated

Expert
opinion

 

Assess intraocular
pressure

…assessment of intraocular pressure in
all individuals with suspected glaucoma,
as it is a significant risk factor for the
development of all forms of glaucoma

Strong

Good

 

Assess optic cup:disc Evidence supports assessment of cup:disc NHMRC
ratio and cup:disc
ratio, and cup:disc ratio asymmetry,
ratio symmetry
when assessing the risk of glaucomatous
damage occurring…
Evidence supports the value of validated
optic disc comparison techniques
(simultaneous stereo photograph
comparison and confocal scanning laser
tomography) in order to detect longitudinal
changes in the optic nerve

Intermediate

Moderate  

Gonioscopy of both
eyes

Weak

Expert
opinion

…gonioscopic examination of both eyes
is required when making a diagnosis of
glaucoma

NHMRC

NHMRC

NHMRC

 

Continued
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Table 3 Continued
Assessment or
intervention name

Recommendation

CPG

SoR

QoE

Remarks on recommendation

Visual field testing

…visual field testing is invaluable to
diagnose glaucoma…advancing age,
visual acuity, patient capability, concurrent
ocular conditions, oculo-facial anatomy
and spectacle scotomata all impact on
the results and interpretation of visual field
testing

NHMRC

Weak

Expert
opinion

 

Assess target
intraocular and reduce
if glaucomatous
progression identified

…assess target intraocular pressure at
each ocular review, within the context of
glaucomatous progression and quality
of life. Evidence strongly supports a
further 20% reduction in target intraocular
pressure when glaucomatous progression
is identified

NHMRC

Strong

Good

 

Topical beta-blockers

Evidence supports using beta-blockers in
infants and children where necessary

NHMRC

Intermediate

Low

To limit potential adverse effects,
it is important to adhere to dosage
times, use nasolacrimal system
occlusion (if at all possible in small
children) and use the minimum
dose or limit the number of
medications required.

Topical beta-
blockers—
precautions

NHMRC
Evidence suggests using beta-blockers
with caution in premature and small
infants, as bradycardia, bronchospasm and
hypoglycaemia have been reported

Intermediate

Low

To limit potential adverse effects,
it is important to adhere to dosage
times, use nasolacrimal system
occlusion (if at all possible in small
children) and use the minimum
dose or limit the number of
medications required.

Carbonic anhydrase
inhibitors

Evidence indicates caution when using
topical and systemic carbonic anhydrase
inhibitors in children, in situations where
glaucoma is resistant to other treatment
and/or prior to surgery

NHMRC

Intermediate

Low

To limit potential adverse effects,
it is important to adhere to dosage
times, use nasolacrimal system
occlusion (if at all possible in small
children) and use the minimum
dose or limit the number of
medications required.

Tube surgery

► Evidence strongly supports using
tube surgery for long-term intraocular
pressure control. This is an appropriate
first-choice surgery in patients:
– with eyes at higher risk of failure
from trabeculectomy;
– who have failed trabeculectomy;
– with iridocorneal endothelial
syndrome;
– with various forms of uveitic
(inflammatory) glaucoma.
► With aphakic glaucoma.

NHMRC

Strong

Moderate Tube surgery should be
considered for the primary
procedure in patients in whom
trabeculectomy is likely to fail,
such situations include some
severely traumatised eyes and
secondary paediatric glaucomas.

AAO, American Academy of Ophthalmology; AOA, American Optometric Association; CPG, clinical practice guideline; NHMRC, National Health and
Medical Research Council; QoE, quality of evidence (good, moderate, low expert opinion); SoR, strength of recommendation (strong, intermediate,
weak); USPSTF, United States Preventive Services Task Force.

this recommendation could also be based on evidence
of the effectiveness of tube surgery in adult populations.
DISCUSSION
The findings of this systematic review demonstrate that
there is a lack of high-quality CPGs aimed at childhood
glaucoma. The evidence to formulate recommendations
for childhood glaucoma varied substantially, with recommendations related to interventions for the treatment of
childhood glaucoma generally of lower-quality evidence
6

compared with recommendations for assessments to
detect childhood glaucoma (and other paediatric eye
disease). In 2013, The World Glaucoma Association
(WGA) formulated consensus guidelines that define
childhood glaucoma and bring a more uniform set of
terminology to the childhood glaucoma landscape.7
While extremely valuable for the field, the WGA
consensus document did not pass the PECI inclusion
criteria as no formal systematic review was conducted.
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Our review indicates much work still needs to be done
to develop strong evidence to inform the development
of CPGs.
The number of randomised controlled trials (RCTs)
for childhood glaucoma has seen only a marginal
increase in the last decade. A recent Cochrane review
identified 16 RCTs or quasi-
RCTs comparing various
surgical interventions for PCG; however, these studies
variously compared 9 different surgical interventions and
generally had low sample size, making it difficult to draw
definite conclusions.20 It is also important to address the
lack of long-term data on the outcomes of these interventions as childhood glaucoma has potentially lifelong
consequences. Measurement of quality of life metrics in
future studies with a medium-term to long-term follow-up
would be of use.
The results of this review indicate that there is a
consensus on the need for children to have an eye examination, conducted by either an eye care professional or
as part of a screening programme, to detect paediatric
eye diseases. However, these recommendations were not
specifically targeted at childhood glaucoma. Limited
long-term trends have shown that screening programmes
such as the retinopathy of prematurity programme, now
mandatory in several countries, may reduce the burden
of disease and potential blindness.21 22 As childhood glaucoma can constitute a multitude of ocular and systemic
conditions, early examination of asymptomatic children
in the population could potentially increase the chances
of early detection and management of these conditions.
However, the low incidence of childhood glaucoma
means that many children would need to be examined
(approximately 20 000–33 000) to detect a single case of
childhood glaucoma and, from a public health perspective, the costs may not outweigh the benefits. A potential
alternative to lower the cost and optimise delivery of these
annual screenings would be to combine these visits with
vaccination programmes or other currently implemented
programmes.23 It is also important to consider who will
perform childhood eye screening or assessments. The
two guidelines on paediatric eye evaluations from the
USA recommends that primary care providers perform
a basic eye screen of newborns and infants,18 24 whereas
it may be more appropriate for children at high risk of
childhood glaucoma to be examined by an ophthalmologist in a secondary or tertiary care setting.
Tube surgery was strongly recommended by the Australian CPG for long-
term IOP control of all glaucoma,
including some childhood glaucomas. The remaining
recommendations for management of childhood glaucoma made in this CPG were of weak or intermediate
strength and generally had only low-quality evidence or
were based on expert opinion. Furthermore, this Australian CPG was published 10 years ago and, based on the
exclusion criteria for this review, is nearly out-of-date. Some
recent evidence indicates that the IOP-lowering response
to antiglaucoma drugs is often lower in children and thus
surgical management is necessary.18 It is also important

to note that serious side effects can occur in children due
to difference in drug pharmacodynamics and pharmacokinetics in children as compared with adults. Use of
low-dose preparations, gel-based formulations, punctal
occlusion during administration and frequent follow-ups
can improve outcomes.25 Notable interventions for which
formal recommendations (for or against) were not made
include trabeculotomy, goniotomy and topical brimonidine eye drops. These interventions were briefly and
informally discussed within the Australian guidelines, but
as no formal recommendation was made, did not meet
the criteria for data extraction. The Australian guideline informally recommended against the use of alpha-2
agonists, such as brimonidine, in children <7 years of age
due to side effects and informally suggested goniotomy
or trabeculotomy as potential interventions for PCG. The
absence of a formal recommendation for trabeculotomy
or goniotomy may reflect uncertainty in the evidence
for these interventions at the time, despite their current
widespread use in clinical practice and recommended
use for PCG in the WGA consensus guidelines.7
Childhood glaucoma is a rare, but devastating, disease.
There is generally a lack of high-
quality evidence to
inform the management of childhood glaucoma and
there are few recent, targeted CPGs. CPGs are uniquely
situated to be able to combine evidence from a systematic search of the scientific literature and the opinion
and experience of experts in the field. The latter is
particularly important in childhood glaucoma, where the
evidence is relatively sparse. The WGA consensus guidelines were an important step in providing guidance on
the best-practice management of childhood glaucoma.
However, there is need for a high-quality CPG, incorporating both expert consensus and a systematic search of
the literature. Limitations to this study include the inclusion of only CGPs written in English in the last 10 years,
which have limited the CGPs identified.
CONCLUSION
We identified three high-quality CPGs relevant to childhood glaucoma in this systematic review; however, none
was specifically targeted at childhood glaucoma. There is
a considerable lack of evidence-based guidelines to direct
management of childhood glaucoma. A coordinated
effort is needed to address this lack of quality data with
standardised disease terminology and management strategies to improve outcomes for children with childhood
glaucoma.
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